Management of Dyslipidemia in Chronic Kidney Disease

• Chronic kidney disease (CKD) is a vital risk factor for coronary artery disease (CAD).

• Advance CKD is associated with high CV mortality related to CAD and nonatherosclerotic cardiac disease.

• LAI recommends using statins in patients with CKD stage 3 above the age of 40 years.

• LAI also recommends cautious initiation of statins in statin-naïve patients on dialysis.

• Individual’s predicted longevity has to be kept in mind while initiating statin therapy in end-stage renal disease (ESRD).

• Dose reduction with a decline in glomerular filtration rate.

• Drug interactions with fibrates and anti-rejection medications.

• Frequent monitoring for side effects is required.

• Role of PCSK9 inhibitors: promising, but more data is needed.